The content provided in this video is for informational and educational purposes only. It does not constitute financial advice, investment recommendations, or an offer to buy or sell any securities. All views expressed are those of InsightfulValue and are based on publicly available information believed to be reliable, but no guarantee is made as to its accuracy or completeness. Always conduct your own research or consult a licensed financial advisor before making any investment decisions. Investing in the stock market involves risks, including the loss of principal.
Please be aware that the stock prices displayed on this website represent a curated selection of data. On desktop devices, you will see a wider range of stock prices, while on mobile devices, we provide a more streamlined view for better user experience and readability.
Our focus is on assessing a company's overall value and performance, rather than analyzing price fluctuations, even if we do watch prices in order to find companies trading below their intrinsic value. For more detailed charting and comprehensive market analysis, we recommend consulting a professional financial service or utilizing advanced charting tools.
We strive to provide accurate and timely information, but we encourage you to verify any financial data before making investment decisions.
Overview
and its operations Daiichi Sankyo is a global pharmaceutical company based in Japan. It was founded in 2005 through the merger of two Japanese pharmaceutical companies, Daiichi Pharmaceutical and Sankyo Co., Ltd. The company's global headquarters is located in Tokyo, Japan, and it has several research and development sites in Japan, Germany, and the United States. Daiichi Sankyo is primarily focused on the development of innovative medicines for the treatment of cardiovascular, metabolic, and infectious diseases, as well as oncology. The company also has a strong presence in the over-the-counter and generic drug markets. Daiichi Sankyo operates in more than 20 countries worldwide and has a diverse portfolio of drugs marketed in over 60 countries. The company's global sales in the fiscal year 2020 were approximately 950 billion yen (about $8.8 billion USD). In addition to developing and marketing drugs, Daiichi Sankyo is also actively engaged in research and development collaborations with academic institutions and other pharmaceutical companies. The company's goal is to continue expanding its portfolio and delivering innovative treatment options to patients around the world. Some of Daiichi Sankyo's notable drugs include: - LIXIANA (rivaroxaban), an oral anticoagulant used to prevent and treat blood clots - Thromboreductin (tenecteplase), a clot-dissolving enzyme used to treat heart attacks - EVISTA (raloxifene), a selective estrogen receptor modulator used to treat osteoporosis and reduce the risk of developing breast cancer - RECLAST (zoledronic acid), an intravenous medication used to treat osteoporosis and prevent bone fractures - Benicar (olmesartan medoxomil), a blood pressure medication used to treat hypertension - Oncology drugs, including ENHERTU (trastuzumab deruxtecan), for the treatment of HER2-positive breast and gastric cancer, and pexidartinib, for the treatment of certain types of tumors.
👉 InsightfulValue is a platform for public company analysis.
👉 We provide a database of public companies, with a focus on value investing principles.
👉 We carefully select every company in our database. With only 1988 listed, there's a reason for that.
👉 The reason is simple – we only select the best-performing public companies, true champions. And we know exactly what we mean by "champion."
👉 For us, a champion is a company with strong finances, a history of impressive dividends, great management, and standout products or services. We mean it.
👉 For each company, we have 464 questions and answers covering every aspect of their market position and operations. Everything.
👉 ... plus additional 98 Q&A about the industry each company operates in.
InsightfulValue is an independent platform dedicated to value investing research. The information provided on this website is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. We are not financial advisors, investment consultants, or licensed consultants. Our analyses, insights, and criteria are based on principles learned from renowned value investors such as Benjamin Graham, Warren Buffett, and Charlie Munger, but they should not be considered personalized investment recommendations. Investing in financial markets carries risks, and past performance is not indicative of future results. Users of this website should conduct their own due diligence and consult with a qualified professional before making any financial or investment decisions. InsightfulValue assumes no liability for any financial losses or decisions made based on the information provided on this site. By using this website, you acknowledge and accept that all investments involve risk and that InsightfulValue does not guarantee any financial outcomes.
